Last reviewed · How we verify

NCT04672018: CT

Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis

Completed Phase 2 Last updated 18 April 2023
What this trial tests

Phase 2 trial testing Houtou Jianweiling tablet in Gastritis in 240 participants. Completed in 2 February 2023.

Timeline
8 November 2022
Primary endpoint
2 February 2023
2 February 2023

Quick facts

Lead sponsorUniversity of Karachi
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment240
Start date8 November 2022
Primary completion2 February 2023
Estimated completion2 February 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

University of Karachi

Who can join

Adults 18 to 65, any sex, with Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the efficacy \& safety of Houtou Jianweiling tablet through the non-inferiority clinical trial of Houtou Jianweiling tablet with Omeprazole Enteric-coated tablet in patients with chronic non-atrophic gastritis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The safety and efficacy of Houtou Jianweiling tablet in patients with chronic non-atrophic gastritis: a double-blind, non-inferiority, randomized controlled trial.
    Shah MR, Fatima S, Khan SN, Shafiullah, et al · · 2024 · cited 1× · PMID 38440179 · DOI 10.3389/fphar.2024.1293272

Verify or expand the search:

Other recruiting trials for Gastritis

Currently open trials in the same condition.

Other University of Karachi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04672018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing